NewAmsterdam Pharma Company N.V. (NAMSW) News
Follow NewAmsterdam Pharma Company N.V. (NAMSW) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
NewAmsterdam Pharma doses first participant in Phase 2b SPINOZA trial
NewAmsterdam Pharma dosed the first participant in its Phase 2b SPINOZA trial evaluating obicetrapib in preclinical Alzheimer’s disease.
EQUITY | Sep 29, 2026, 12:03 PM UTC
L
NAMS NAMSW - NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed- Dose Combination)
NAMS NAMSW - NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed- Dose Combination)
NEWS | Sep 21, 2026, 01:01 PM UTC
L
NewAmsterdam Pharma reports inducement grants under Nasdaq Rule 5635(c)(4)
NewAmsterdam Pharma reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 03, 2026, 08:01 PM UTC
L
NAMS NAMSW - NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
NAMS NAMSW - NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
EQUITY | Sep 02, 2026, 12:00 PM UTC
H
NAMS NAMSW - NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Click For Rele
NAMS NAMSW - NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
GEOPOLITICS | Aug 26, 2026, 12:00 PM UTC
L
NAMS NAMSW - NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
NAMS NAMSW - NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
EARNINGS | Aug 05, 2026, 11:00 AM UTC
L
NAMS NAMSW - NewAmsterdam Pharma to Host Investor Day on August 5, 2026
NAMS NAMSW - NewAmsterdam Pharma to Host Investor Day on August 5, 2026
EQUITY | Jul 29, 2026, 12:00 PM UTC